Search results for "preserved ejection fraction"

showing 10 items of 43 documents

Permanent left atrial pacing therapy may improve symptoms in heart failure patients with preserved ejection fraction and atrial dyssynchrony: a pilot…

2012

Aims Our group has recently shown that in some patients, heart failure with preserved ejection fraction (HFPEF) may be explained by ‘atrial dyssynchrony syndrome’ (ADS) due to interatrial conduction delay (IACD), a short left atrioventricular interval (LAVI), and increased left atrial (LA) stiffness. Our primary objective was to evaluate LA pacing therapy as a new treatment to restore left ventricular active filling in patients with no other known causes for HF than ADS. Methods and results Six patients with severe HFPEF with IACD (P wave duration >120 ms in lead II), short LAVI during electrophysiological studies ( 15), and no standard indication for a pacemaker were implanted with a lead …

Malemedicine.medical_specialtyPilot ProjectsSeverity of Illness IndexHeart RateInternal medicineAtrial FibrillationHeart ratemedicineHumansHeart AtriaCoronary sinusAgedHeart FailureCross-Over StudiesEjection fractionbusiness.industryCardiac Pacing ArtificialStroke VolumeAtrial fibrillationStroke volumemedicine.diseaseCrossover studyTreatment OutcomeHeart failureCardiologyFemaleFranceCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionEuropean Journal of Heart Failure
researchProduct

Burden of Recurrent Hospitalizations Following an Admission for Acute Heart Failure: Preserved Versus Reduced Ejection Fraction.

2017

Abstract Introduction and objectives Heart failure with preserved ejection fraction and reduced ejection fraction share a high mortality risk. However, differences in the rehospitalization burden over time between these 2 entities remains unclear. Methods We prospectively included 2013 consecutive patients discharged for acute heart failure. Of these, 1082 (53.7%) had heart failure with preserved ejection fraction and 931 (46.2%) had heart failure with reduced ejection fraction. Cox and negative binomial regression methods were used to evaluate the risks of death and repeat hospitalizations, respectively. Results At a median follow-up of 2.36 years (interquartile range: 0.96-4.65), 1018 pat…

Malemedicine.medical_specialtyanimal structures030204 cardiovascular system & hematologyPatient Readmission03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineCost of IllnessInterquartile rangeRecurrenceInternal medicinemedicineHumans030212 general & internal medicineAgedHeart FailureEjection fractionbusiness.industryStroke VolumeGeneral Medicinemedicine.diseaseConfidence intervalHospitalizationHeart failureAcute DiseaseCardiologyFemalebusinessHeart failure with preserved ejection fractionRevista espanola de cardiologia (English ed.)
researchProduct

Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction

2018

Aims The mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF) are not yet elucidated. Chronotropic incompetence has emerged as a potential mechanism. We aimed to evaluate whether heart rate (HR) response to exercise is associated to functional capacity in patients with symptomatic HFpEF. Methods and results We prospectively studied 74 HFpEF patients [35.1% New York Heart Association Class III, 53% female, age (mean ± standard deviation) 72.5 ± 9.1 years, and 59.5% atrial fibrillation]. Functional performance was assessed by peak oxygen consumption (peak VO2 ). The mean (standard deviation) peak VO2 was 10 ± 2.8 mL/min/kg. The following chronotropic pa…

Chronotropicmedicine.medical_specialtybusiness.industryAtrial fibrillationExercise intolerance030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineInternal medicineHeart failureHeart ratemedicineCardiologyIn patient030212 general & internal medicinemedicine.symptomCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionESC Heart Failure
researchProduct

Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: The TRAINING-HF Tr…

2019

Introduction and objectives: Despite the prevalence of heart failure with preserved ejection fraction (HFpEF), there is currently no evidence-based effective therapy for this disease. This study sought to evaluate whether inspiratory muscle training (IMT), functional electrical stimulation (FES), or a combination of both (IMT + FES) improves 12- and 24-week exercise capacity as well as left ventricular diastolic function, biomarker profile, and quality of life in HFpEF. Methods: A total of 61 stable symptomatic patients (New York Heart Association II-III) with HFpEF were randomized (1:1:1:1) to receive a 12-week program of IMT, FES, or IMT + FES vs usual care. The primary endpoint of the st…

MaleQuality of lifemedicine.medical_specialtyAftercareElectric Stimulation Therapy030204 cardiovascular system & hematologyBreathing Exercises03 medical and health sciences0302 clinical medicineOxygen ConsumptionQuality of lifeInternal medicineSurveys and QuestionnairesClinical endpointExercise capacityMedicineFunctional electrical stimulationHumansAerobic capacityAgedHeart FailureExercise Tolerancebusiness.industryInspiratory muscle trainingStroke VolumeGeneral MedicineExercise capacityCombined Modality TherapyTreatment OutcomeHeart failure with preserved ejection fractionEchocardiographySample SizeCardiologyBiomarker (medicine)FemalebusinessHeart failure with preserved ejection fractionPhysical therapy
researchProduct

Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease.

2012

Abstract Aims and background Midregional proadrenomedullin (MR-proADM) is a protein, which exerts various effects on the cardiovascular system. Recent studies underscored its prognostic implications in patients with acute dyspnea and cardiovascular diseases. Therefore, we aimed to determine the distribution of MR-proADM in the general population and to reveal potential associations of MR-proADM with cardiovascular risk factors and measures of subclinical cardiovascular disease. Methods and results MR-proADM plasma concentrations were determined in individuals of the population-based cohort of the Gutenberg Health Study ( N  = 5000) using a commercially available fluoroimmunoassay. Individua…

AdultMalemedicine.medical_specialtyPopulationFluoroimmunoassayRisk AssessmentCoronary artery diseaseAdrenomedullinSex FactorsPredictive Value of TestsRisk FactorsInternal medicineGermanymedicinePrevalenceHumansMyocardial infarctionProspective StudiesProtein PrecursorseducationSubclinical infectionAgededucation.field_of_studybusiness.industryAge FactorsMiddle Agedmedicine.diseasePrognosisPeptide FragmentsUp-RegulationCross-Sectional StudiesPhenotypeIntima-media thicknessCardiovascular DiseasesEchocardiographyHeart failureAsymptomatic DiseasesCardiologyLinear ModelsPopulation studyFemaleCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionBiomarkersAtherosclerosis
researchProduct

Evaluation of a novel biomarker of type XXVIII collagen formation, PRO-C28, in samples from cancer and heart failure with preserved ejection fraction…

2020

Increased turnover of extracellular matrix proteins is seen in many different diseases and is an underlying and driving feature of pathogenesis. An increased ratio of formation over degradation of extracellular matrix proteins, such as collagens, leads to accumulation of proteins in the tissues, ultimately impairing organ function. Understanding how this balance is regulated is key to providing deeper insight into high extracellular matrix turnover diseases. Type XXVIII collagen is a novel collagen with limited information available in relation to expression, tissue prevalence and clinical implication. We generated a novel, technically robust ELISA to measure a C-terminal fragment of type X…

Heart Failuremedicine.medical_specialtyChemistryClinical BiochemistryPharmaceutical ScienceCancerStroke Volumemedicine.diseasePeptide FragmentsAnalytical ChemistryPathogenesisExtracellular matrixCollagen formationEndocrinologyInternal medicineNeoplasmsDrug DiscoverymedicineBiomarker (medicine)HumansIn patientLung cancerHeart failure with preserved ejection fractionSpectroscopyBiomarkersJournal of pharmaceutical and biomedical analysis
researchProduct

Peak Exercise Oxygen Uptake Predicts Recurrent Admissions in Heart Failure With Preserved Ejection Fraction

2018

Introduction and objectives: Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent syndrome with an elevated risk of morbidity and mortality. To date, there is scarce evidence on the role of peak exercise oxygen uptake (peak VO2) for predicting the morbidity burden in HFpEF. We sought to evaluate the association between peak VO2 and the risk of recurrent hospitalizations in patients with HFpEF. Methods: A total of 74 stable symptomatic patients with HFpEF underwent a cardiopulmonary exercise test between June 2012 and May 2016. A negative binomial regression method was used to determine the association between the percentage of predicted peak VO2 (pp-peak V02) and rec…

Malemedicine.medical_specialtyMultivariate analysis030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineOxygen ConsumptionInterquartile rangeRecurrenceInternal medicinemedicineHumans030212 general & internal medicineProspective StudiesProspective cohort studyExercisePeak exerciseAgedHeart Failurebusiness.industryStroke VolumeGeneral MedicineStroke volumemedicine.diseaseOxygen uptakeHospitalizationHeart failureCardiologyExercise TestFemalebusinessHeart failure with preserved ejection fraction
researchProduct

Role of functional mitral regurgitation in heart failure with preserved ejection fraction: an unrecognized protagonist?

2016

Heart Failuremedicine.medical_specialtybusiness.industryMitral Valve InsufficiencyStroke VolumeStroke volume030204 cardiovascular system & hematologymedicine.diseaseVentricular Function Left03 medical and health sciences0302 clinical medicineInternal medicineHeart failuremedicineCardiologyHumans030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionFunctional mitral regurgitationEuropean Journal of Heart Failure
researchProduct

Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism

2020

Abstract Aims This study aimed to investigate whether the risk of short‐term mortality is different in pulmonary embolism (PE) patients who have heart failure with reduced ejection fraction (HFrEF) as compared with those with heart failure with preserved ejection fraction (HFpEF). Methods and results Predictive value of HFrEF or HFpEF for 7‐day (intrahospital) and 30‐day all‐cause mortality was determined in the cohort of 1055 out of 1201 consecutive acute PE patients from the Serbian multicentre PE registry. Patients were classified into either HFrEF or HFpEF group, according to guideline‐proposed criteria. A 7‐day (intrahospital) and 30‐day all‐cause mortality was 18.5% vs. 7.3% vs. 4.5% …

Ejection fractionmedicine.medical_specialtyHeart failure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineOriginal Research ArticlesInternal medicineDiseases of the circulatory (Cardiovascular) systemMedicineOriginal Research Article030212 general & internal medicineMortalityRisk factorEjection fractionbusiness.industryPulmonary embolismHazard ratioAtrial fibrillationmedicine.disease3. Good healthPulmonary embolismBlood pressureRC666-701Heart failureCardiologyCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionESC Heart Failure
researchProduct

Protective Effects of a Discontinuous Treatment with Alpha-Lipoic Acid in Obesity-Related Heart Failure with Preserved Ejection Fraction, in Rats

2020

Obesity induces hemodynamic and humoral changes that are associated with functional and structural cardiac remodeling, which ultimately result in the development of heart failure (HF) with preserved ejection fraction (HFpEF). In recent years, pharmacological studies in patients with HFpEF were mostly unsatisfactory. In these conditions, alternative new therapeutic approaches are necessary. The aim of our study was (1) to assess the effects of obesity on heart function in an experimental model and (2) to evaluate the efficacy of an alpha-lipoic acid (ALA) antioxidant treatment. Sprague-Dawley rats (7 weeks old) were either included in the control group (n = 6) or subjected to abdominal aorti…

heart failure with preserved ejection fraction0301 basic medicineobesitymedicine.medical_specialtyPhysiologymedicine.drug_classClinical BiochemistryDiastoleHemodynamics030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineNatriuretic peptideoxidative stressMolecular BiologyEjection fractionAdiponectinbusiness.industryalpha-lipoic acidlcsh:RM1-950Cell Biologymedicine.diseaselcsh:Therapeutics. Pharmacologyantioxidants030104 developmental biologyEndocrinologyHeart failurebusinessHeart failure with preserved ejection fractionOxidative stressAntioxidants
researchProduct